Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

Jolles, Stephen, Borte, Michael, Nelson, Robert P., Rojavin, Mikhail, Bexon, Martin, Lawo, John-Philip and Wasserman, Richard L. 2014. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease. Clinical Immunology 150 (2) , pp. 161-169. 10.1016/j.clim.2013.10.008

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (296kB) | Preview

Abstract

Hizentra® (20% subcutaneous immunoglobulin [SCIG]) was administered to subjects with primary immunodeficiency disease in two extension studies in the EU and US to assess long-term efficacy and tolerability. Subjects (aged 4–69 years) were treated for 148 weeks in the EU (N = 40; 5405 infusions) and 87 weeks in the US (N = 21; 1735 infusions). Weekly doses were 116.0 mg/kg (EU) and 193.2 mg/kg (US); IgG levels were 7.97 g/L (EU) and 11.98 g/L (US). Annualized rates of serious bacterial infections were 0.05 infections/subject/year (EU) and 0.06 infections/subject/year (US). Rates of any infection were 3.33 infections/subject/year (EU) and 2.38 infections/subject/year (US). The rate of bronchopulmonary infections was higher in the EU study. No treatment-related serious AEs occurred; no subject discontinued because of treatment-related AEs. Self-administered Hizentra afforded sustained effective protection from infections and favorable tolerability during an extended treatment period of up to 3 years.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	1521-6616
Funders:	CSL Behring
Date of First Compliant Deposit:	7 January 2019
Date of Acceptance:	15 October 2013
Last Modified:	05 May 2023 18:01
URI:	https://orca.cardiff.ac.uk/id/eprint/117935

Citation Data

Cited 23 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item